Two different *BRCA2* mutations found in a multigenerational family with a history of breast, prostate, and lung cancers

Diane A Caporale
Erica E Swenson

Department of Biology, University of Wisconsin – Stevens Point, Stevens Point, WI, USA

Abstract: Breast and lung cancer are two of the most common malignancies in the United States, causing approximately 40,000 and 160,000 deaths each year, respectively. Over 80% of hereditary breast cancer cases are due to mutations in two breast cancer predisposition genes, *BRCA1* and *BRCA2*. These are tumor-suppressor genes associated with DNA repair. Since the discovery of these two genes in the mid-1990s, several other breast cancer predisposition genes have been identified, such as the *CHEK2* gene encoding a regulator of *BRCA1*. Recently, studies have begun investigating the roles of *BRCA1* and *BRCA2* gene expression in lung cancer. We conducted a family-based case study that included a bloodline of Italian heritage with several cases of breast cancer and associated cancers (prostate and stomach) through multiple generations and on a nonblood relative of Scottish/Irish descent who was consecutively diagnosed with breast and lung cancer. Cancer history and environmental risk factors were recorded for each family member. To investigate possible genetic risks, we screened for mutations in specific hypervariable regions of the *BRCA1*, *BRCA2*, and *CHEK2* genes. DNA was extracted and isolated from the individuals' hair follicles and cheek cells. Polymerase chain reaction (PCR), allele-specific PCR, and DNA sequencing were performed to identify and verify the presence or absence of mutations in these regions. Genotypes of several family members were determined and carriers of mutations were identified. Here we report for the first time the occurrence of two different *BRCA2* frameshift mutations within the same family. Specifically, three Italian family members were found to be carriers of the *BRCA2*-c.2808_2811delACAA (3036delACAA) mutation, a 4-nucleotide deletion in exon 11, which is a truncated mutation that causes deleterious function of *BRCA2*. This mutation that has been reported in many women of Spanish descent is within a hotspot and is predicted to have resulted from three separate mutational events. Although sporadic mutations can occur, more than likely it is the result of a germ line mutation inherited from the Italian family line and was carried by a father that died of prostate cancer. Since individual III-2 had an early onset of breast cancer, it is recommended that siblings of II-1 seek genetic counseling and be screened for the *BRCA2*-3036delACAA variant. The individual with breast and lung cancer (II-8) was not a carrier of this mutation, but rather a carrier of the *BRCA2*-c.6275_6276delTT (6503delTT), which is also a truncated mutation but more common in those of Irish/Scottish descent. It is recommended that her immediate family members be screened for this mutation to assess their risk of breast cancer. We conclude that DNA screening of the *BRCA2* promoter region and the *BRCA2*-6503delTT site from a lung tumor biopsy taken from individual II-8 would provide more insight into the possible association of this *BRCA2* variant with lung cancer.

Keywords: breast/prostate/lung cancers, *BRCA2* deletions, AS PCR, genogram

Correspondence: Diane A Caporale
Department of Biology, University of Wisconsin – Stevens Point, 800 Reserve Street, Stevens Point, WI 54481, USA
Tel +1 715 346 3922
Fax +1 715 346 3624
Email dcaporal@uwsp.edu

Introduction

The two most common malignancies in the United States are breast cancer and lung cancer, which cause nearly 40,000 and 160,000 deaths each year, respectively.¹

Up to 10% of breast cancer cases are hereditary, with over 80% of those cases due to mutations in two breast cancer predisposition genes, *BRCA1* and *BRCA2*.^{2,3} Researchers have established a strong association between numerous mutations in the *BRCA1* and *BRCA2* genes and the risk of developing breast cancer as well as ovarian, pancreatic, prostate, and stomach/pancreatic cancers.⁴ Recently, studies have begun investigating the role of epigenetics with varying *BRCA1* and *BRCA2* expression in non-small cell lung cancer.⁵⁻⁹

The *BRCA1* and *BRCA2* genes, located on chromosome 17 and 13, respectively, are tumor suppressor genes encoding large proteins involved in the TP53 signal transduction pathway that repairs double-strand breaks in DNA.^{8,10} Mutations of these genes can result in non- or dysfunctional proteins, leading to tumor growth and cancer. As listed in the Breast Cancer Information Core (BIC) database, clinically important *BRCA1* mutations are often frameshift mutations, resulting in a truncated nonfunctional protein. The mutation has an inheritance pattern of autosomal dominant, which predisposes one to earlier onset of breast tumors.¹¹ In addition, the incidence of *BRCA1* varies between different populations, suggesting it interacts with other proteins and environmental factors. A large number of studies have looked at variants of the *BRCA1* and *BRCA2* genes to determine if a specific mutation is of clinical significance. By 2010, over 750 clinically important mutations have been identified in *BRCA2*.² Because of the sheer number of mutations, many studies have scanned the entirety of the *BRCA2* gene using sequence analysis to identify mutations. In addition, several researchers

have examined how *BRCA1/2* promoter hypermethylation, which reduces levels of *BRCA1/2* messenger RNA, is related to lung cancer tumor growth.⁸

Since the discovery of the *BRCA1* and *BRCA2* genes in 1994 and 1995, respectively, several other breast cancer predisposition genes have been identified.¹² The *CHEK2* gene, located on chromosome 22, encodes DNA replication checkpoint kinase 2, which is an upstream regulator of *BRCA1* and TP53. As expected, mutations of the *CHEK2* gene have also been associated with a variety of cancers. Consequently, researchers have analyzed specific variants to determine the association between specific mutations and the risk of different types of cancer.¹³ A strong association between several mutations in the *BRCA1/2* and *CHEK2* genes has been established with the risk of developing breast cancer as well as ovarian, prostate, pancreatic, stomach, and colon cancer.⁴ In addition, *CHEK2* mutations have been frequently found in women with hereditary breast cancer who tested negative for *BRCA1* and *BRCA2* mutations.¹⁴

As illustrated in the pedigree in Figure 1, individual III-9 (the ninth individual from the third generation) of Italian descent is a 6-year breast cancer survivor whose breast cancer recently recurred. Her deceased father had prostate cancer, his sister had breast cancer twice, and his father had stomach cancer. A nonblood relative of Scottish/Irish decent, individual II-8 is a breast cancer survivor who was most recently diagnosed with non-small cell lung cancer. Individual III-9 received genetic testing by Myriad Genetics (Salt Lake City, Utah, USA) and tested positive for the

Figure 1 Pedigree of a family of Italian descent showing strong family history of breast cancer.

Notes: Red symbols represent cancer cases that were either tested positive or are possible carriers of the *BRCA2*-3036delACAA mutation. Brown symbols represent cancer cases that were either tested negative or more than likely are not carriers of the *BRCA2*-3036delACAA variant. The orange symbol represents an individual with breast and lung cancer and a carrier of the *BRCA2*-6503delTT variant. Ages of disease onset are shown in years next to the cancer type. II-8 and III-9 are focus references. '+' indicates individual heterozygous for a *BRCA2* variant; '-' indicates individual homozygous wild-type for both *BRCA2* regions screened in this study. Roman numerals I-V represent generations and numbers 1-13 represent the individuals within each generation.

BRCA2-c.2808_2811delACAA (3036delACAA) mutation. This frameshift mutation results in an early stop codon at amino acid position 958 of the *BRCA2* protein, thus rendering it nonfunctional. We investigated the inheritance of the *BRCA2*-3036delACAA mutation throughout her extended family to assess their risk of developing breast cancer and other associated cancers, such as prostate and stomach cancer identified within the family. Participants were also screened for two variants of the *CHEK2* gene, the (I157T) missense variant and (1100delC) truncating variant. Although mutations in *CHEK2* are rarer than *BRCA* mutations, *CHEK2* founder mutations from eastern Europe were also included in the study based on their association with an increased risk of breast, prostate, and stomach cancer, which were experienced in this extended family.¹³ In addition, we screened II-8's DNA for possible *BRCA1* or *BRCA2* mutations typically found in Scottish and Irish populations to help provide insight into a possible genetic cause for her breast and lung cancers.^{15–17}

Materials and methods

DNA isolation

DNA was isolated using the Qiagen (Valencia, CA, USA) DNeasy Kit. At least ten hair follicles from each individual were first washed in 100% ethanol and then placed in ATL lysis buffer and 30 µL of proteinase K. Samples were incubated at 55°C overnight. DNA was purified using spin columns and following the manufacturer's instructions. Finally, products were eluted with 30 µL of Buffer AE. DNA concentrations were determined spectrophotometrically using a Thermo Scientific Nanodrop 1000 (Thermo Fisher Scientific, Waltham, MA, USA) and ranged from 50 ng/µL to 150 ng/µL.

Polymerase chain reaction and DNA sequencing

A 257-base pair (bp) portion of exon 11 of the *BRCA2* gene was amplified using primers that were designed to flank the (3,036–3,039)-nucleotide region, where the 4-bp deletion would be located. National Center for Biotechnology Information GenBank accession # NM_000059.3 was used as a reference sequence of the *BRCA2* gene, with the amplicon corresponding to region 26,613–26,869. The forward primer was *BRCA2*-3036del4-f: (5'-GACTTGACTTGTGTAAACG AACCC-3'), whereas the reverse primer was *BRCA2*-3036del4-r: (5'-CCTAAGAGTCCTGCCCCATTTGTTC-3'). Between 50 ng and 100 ng of DNA was used in each polymerase chain reaction (PCR), which included a final concentration of 1× GoTaq® buffer (Promega Corporation, Fitchburg, WI, USA), 1.5 mM MgCl₂, 0.2 mM of each deoxynucleoside

triphosphate, 1 U of GoTaq® polymerase (Promega), 1 µM of each forward and reverse primer, and enough deionized water to reach a final volume of 25 µL. PCRs were performed in an MJ Research PTC100 thermocycler (Waltham, MA, USA). Samples were denatured at 94°C for 5 minutes, followed by 94°C for 30 seconds, annealed at 60°C for 60 seconds, and extended at 72°C for 120 seconds for 40 cycles, and ended with a final extension at 72°C for 5 minutes.

The *CHEK2* gene was also screened for two founder mutations, (p.I157T) and (p.1100delC), using primer pairs as described by Cybulski et al.¹³ PCR conditions were the same as previously described, except the annealing temperature was 50°C. To verify amplification, 10 µL of each sample, a negative control, and a positive control, with each containing 2 µL of Orange G loading dye (NewEngland BioLabs, Ipswich, MA, USA), were separated by electrophoresis on a 1% Bio-Rad (Hercules, CA, USA) agarose gel containing ethidium bromide and 1×TAE (Tris acetate-ethylenediaminetetraacetic acid) and visualized on a BioRad transilluminator (Hercules, CA, USA). The remaining 15 µL of PCR product was then purified using Diffinity RapidTips (Sigma-Aldrich, St Louis, MO, USA). Samples were cycle-sequenced using Taq polymerase-mediated incorporation of dye-labeled dideoxy terminators. Sequencing reactions contained approximately 50 ng of DNA, 4 µL of BigDye Terminator v1.1 cycle sequencing kit (Life Technologies, Grand Island, NY, USA), and 1 µM of forward primer. Reverse reactions were also performed using reverse nested primers for each nested PCR product. Components were denatured at 96°C for 30 seconds, annealed at 50°C for 15 seconds, and extended at 60°C for 4 minutes, for a total of 25 cycles. Samples were run through Centri-Sep columns (Princeton Separations, Adelphia, NJ, USA) to remove unincorporated nucleotides and then lyophilized. Purified DNA samples were prepared for sequencing and were electrophoresed as previously described. Using Sequencing Analysis version 5.3.1 (Applied Biosystems) and Geneious v4.6.4 (Biomatters, Auckland, New Zealand) software, forward and reverse DNA electropherograms were aligned and edited. Consensus sequence was then compared with normal *BRCA2* sequence (GenBank accession # NC_000013). A genogram was constructed using Geneious v4.6.4 to illustrate the inheritance of the *BRCA2*-3036delACAA mutation within the extended family.

Allele-specific PCR

The DNA from the woman of Scottish/Irish descent (II-8), who had breast and lung cancers, was screened for the *BRCA1*-c.2681-2682delAA (2800delAA) and

BRCA2-c.6275_6276delTT (6503delTT) mutations. Allele-specific (AS) primers were designed to include the deletions in the forward primer for each *BRCA2* site. AS primer names and nucleotide sequences are listed in Table 1. Forward primers that were normal and containing the mutation were paired with a reverse primer that matched each of their melting temperatures.

The protocol for each AS PCR was the same as previously described, with one modification: annealing temperatures for *BRCA1*-2800delAA and *BRCA2*-6503delTT were 51°C and 58°C, respectively (Table 1). A positive control (human DNA containing mutation) and negative control (Nanopure water; Barnstead, Thermo Scientific) were used with each primer pair. To verify PCR results, amplicons were sequenced using the methods described earlier.

Results

BRCA2-c.2808_2811delACAA (3036delACAA) screening

Using the program Sequencing Analysis 5.3.1, each participant's DNA sequences of the *BRCA2*-3036delACAA region were analyzed. As seen in Figure 2, the electropherogram on the bottom is indicative of a normal sequence that does not contain the *BRCA2*-3036delACAA mutation. There is a single broad peak for each base with minimal background noise. The electropherogram on top is indicative of a sequence in which a person contains one normal allele and one allele with the deletion of the four nucleotides, ACAA. The image appears to have two superimposed sequence variants. The smaller peaks beneath each larger peak represent the sequence with the deletion. It is evident that each smaller peak corresponds to the same base as the larger peak that is four bases downstream. This electropherogram pattern was observed in three family members: II-5, III-4, and III-9. The electropherograms from the rest of the participants did

not have the 4-bp deletion and were considered wild-type (Wt). Reverse sequence comparisons verified each of these findings.

AS PCR screening

Based on AS results shown in Figure 3A and B, individual II-8 is homozygous Wt for area *BRCA1*-c.2681-2682delAA (2800delAA). Verification of her genotype was seen in the DNA sequence of this region. II-8's electropherogram in Figure 4 did not have a two-base deletion and contained two adenines at the variant site. In contrast, gel images seen in Figure 5A and B illustrate that II-8 is a heterozygote for the *BRCA2* gene and a carrier of the 6503delTT variant. The TT deletion was verified in the DNA sequence of this *BRCA2* region, seen in Figure 6.

CHEK2 screening

DNA samples from participants were screened for founder mutations *CHEK2*-p.I157T and *CHEK2*-p.I100delC. All of the DNA sequences exhibited the Wt allele for both sites, whereas no missense mutation nor two-base deletion was observed in the electropherograms, respectively.

Discussion

The objectives of this study were to analyze three genes and mutations associated with increased risk of cancer within an extended family with a history of breast, prostate, stomach, and lung cancer. Here we report for the first time the occurrence of two different *BRCA2* frameshift mutations within the same family. DNA sequence analyses of the *BRCA2* gene showed that sequences of individuals who lacked the *BRCA2*- c.2808_2811delACAA (3036delACAA) deletion possessed only one electropherogram image, indicating two Wt alleles for those individuals. However, three individuals in this study (II-5, III-4, and III-9 from Figure 1) were carriers

Table 1 Allele-specific primers used to screen two *BRCA* mutations seen in Great Britain populations

Allele-specific primer	5'–3' sequence	Annealing temp (°C)
<i>BRCA1</i> -2800delAA Wt-f	CCTTAAAGAAACAAAGTCCATGT	51
<i>BRCA1</i> -2800delAA Wt-r	TATTAGGCTAATTGTG	
<i>BRCA1</i> -2800delAA Mut-f	TCCTTAAAGACAAAGTCCA	51
<i>BRCA1</i> -2800delAA Mut-r	TGTTATTACGGCTAATTGTG	
<i>BRCA2</i> -6503delTT Wt-f	ACTTGAGGCCAGAAGTTTGAGGCC	58
<i>BRCA2</i> -6503delTT Wt-r	AGACATTAAAGAGAACTGC	
<i>BRCA2</i> -6503delTT Mut-f	ACGAGGCCAGAAGTTTGAGAAGC	58
<i>BRCA2</i> -6503delTT Mut-r	CAGACATTAAAGAGAACTGC	

Abbreviations: f, forward; r, reverse; Mut, mutation; Wt, wild-type.

Figure 2 Representation of electropherograms of a homozygous wild-type *BRCA2* DNA sequence (bottom) and a heterozygote (top) with a wild-type *BRCA2* DNA sequence superimposed on a *BRCA2*-3036delACAA mutated sequence (seen in individuals II-8, III-4, and III-9).
Note: Pink arrows indicate how the mutated sequence is shifted by four bases downstream of the deletion site.

Figure 3 Gel images of amplicons that included the *BRCA1*-2800delAA region.
Notes: Gel image (A) shows the presence of the wild-type allele. Gel image (B) shows the absence of the *BRCA1*-2800delAA variant. These results reveal II-8's genotype as homozygous wild-type for this region of the *BRCA1* gene.
Abbreviations: +C, positive control; -C, negative control.

Figure 4 Electropherograms of the DNA sequence containing the *BRCA1*-2800delAA mutation in the control DNA and the absence of the AA deletion in II-8's DNA.
Abbreviations: Wt, wild-type; +C, positive control.

Figure 5 Gel images of amplicons that included the *BRCA2*-6503delTT region.
Notes: Gel image (A) shows the presence of the wild-type variant. Gel image (B) shows the presence of the *BRCA2*-6503delTT variant. These results indicate that II-8's genotype is heterozygous for this region of the *BRCA2* gene.
Abbreviations: +C, positive control; -C, negative control.

of the *BRCA2*-3036delACAA variant. The electropherograms for these individuals contained superimposed images, with one shifted by four bases downstream of the deletion site. This *BRCA2* variant is one of the most common germ line mutations reported and is highly prevalent in Spanish families with histories of breast cancer.¹⁸ The deletion site is located within a hairpin secondary structure, rendering it a hotspot for mutation. In order for this four-base deletion to occur, it was predicted to have resulted from three separate mutational events.¹⁸

The *BRCA2*-3036delACAA mutation was found in siblings III-4 and III-9 and their paternal aunt (II-5) of Italian descent. More than likely, siblings III-4 and III-9 inherited this germ line mutation from their father, II-3, and this mutation may have contributed to the cause of their father's prostate cancer, the father's sister's (II-5) two primary incidences of breast cancer, and the father's daughter's (III-9) two primary incidences of breast cancer. The male sibling III-4, who is 62 years of age, is at a substantially higher

risk of prostate cancer. Estimates show up to one-third of male *BRCA2* mutation carriers will get prostate cancer by age 65.

Participants married into the Italian bloodline do not carry this *BRCA2* mutation. Since it is a rare allele in the general population, it may be safe to assume that individuals in generation IV and V have not inherited the *BRCA2*-3036delACAA mutation and will not be passing this allele down to any future generation.

Although the siblings of II-1 and II-2 were not screened, having breast cancer at age 46, individual III-2 may have inherited the *BRCA2*-3036delACAA mutation from her father (II-1). Although her father died of a brain aneurysm before age 50, he may have been a carrier of the mutation. Since individual I-1 died of stomach (and possibly pancreatic – records lack detail) cancer in his 40s, it is possible that he too was a carrier of the mutation, which may have contributed to his cancer and been passed down to at least one or perhaps more of his children. It is recommended that siblings

Figure 6 Electropherogram of II-8's DNA sequence containing the *BRCA2*-6503delTT mutation that is aligned with the DNA sequence of a normal control.
Abbreviations: Wt, wild-type; +C, positive control.

of individual II-1 seek genetic counseling and be screened for the *BRCA2*-3036delACAA variant since they also have children (not illustrated in pedigree) who could have inherited this cancer-susceptibility gene.

Individual II-8, who had breast and lung cancer, was tested positive for the 6503delTT mutation by AS PCR and verified by DNA sequence comparisons. This truncated mutation most likely increased her susceptibility to breast cancer but may not have contributed to her lung cancer. Since it was revealed in her survey that she was a tobacco smoker in her earlier years, we cannot discount the possibility that two somatic mutations occurred within some other cancer-susceptibility gene. Nonetheless, it is recommended that her family members be screened for this mutation to assess their risk of breast cancer and other associated cancers. In addition, *BRCA2*-6503delTT screening of a tumor biopsy from II-8's lung tissue would provide more insight into the possible association of this *BRCA2* variant with lung cancer. Moreover, other founder mutations of the *CHEK2* gene should be investigated as well. Finally, the *BRCA2* promoter should also be screened for any possible mutation that could cause hypermethylation to occur and ultimately downregulate the *BRCA2* gene, as seen in cases of non-small cell lung cancer.

In conclusion, two truncated deleterious *BRCA2* mutations have been identified in a family of Italian and Irish ethnicities, with known cases of breast, prostate, stomach, and lung cancer. Germ line mutations of the *BRCA2* gene substantially increase the lifetime risk of developing breast, ovarian, and prostate cancer. Since any sibling of a germ line mutation carrier has a 50% chance of inheriting the mutation, genetic testing is recommended, whereas results can be used to dictate the level and frequency of screening as well as influence decision-making on preventative measures, such as prophylactic surgery. Further studies on the possible role of *BRCA2* in lung cancer need to be explored.

Acknowledgments

This project was partly funded by the University of Wisconsin-Stevens Point College of Letters and Science Summer Undergraduate Education Initiative provided by D Caporale and the UWSP Student Research Fund. DNA sequencing services were provided by the UWSP Biology Department's Genetic Analysis Service.

Disclosure

The authors report no conflicts of interest in this work.

References

1. Cancer prevention and control: breast cancer [webpage on the Internet]. Atlanta, GA: Centers for Disease Control and Prevention; 2012. Available from: <http://www.cdc.gov/cancer/index.htm>. Accessed August 15, 2013.
2. Lim MJ, Foster GJ, Gite S, Ostendorff HP, Narod S, Rothschild KJ. An ELISA-based high throughput protein truncation test for inherited breast cancer. *Breast Cancer Res*. 2010;12(5):R78.
3. Chenevix-Trench G, Healey S, Lakhani S, et al; kConFab Investigators. Genetic and histopathologic evaluation of *BRCA1* and *BRCA2* DNA sequence variants of unknown clinical significance. *Cancer Res*. 2006;66(4):2019–2027.
4. Lewis R. The genetics of cancer. In: Lewis R, editor. *Human Genetics: Concepts and Applications*. 8th ed. New York: McGraw-Hill; 2008:355–376.
5. Boettger MB, Sergi C, Meyer P. *BRCA1/2* mutation screening and LOH analysis of lung adenocarcinoma tissue in a multiple-cancer patient with a strong family history of breast cancer. *J Carcinog*. 2003;2(1):5.
6. Marsit CJ, Liu M, Nelson HH, Posner M, Suzuki M, Kelsey KT. Inactivation of the Fanconi anemia/*BRCA* pathway in lung and oral cancers: implications for treatment and survival. *Oncogene*. 2004;23(4):1000–1004.
7. Taron M, Rosell R, Felip E, et al. *BRCA1* mRNA expression levels as an indicator of chemoresistance in lung cancer. *Hum Mol Genet*. 2004;13(20):2443–2449.
8. Lee MN, Tseng RC, Hsu HS, et al. Epigenetic inactivation of the chromosomal stability control genes *BRCA1*, *BRCA2*, and *XRCC5* in non-small cell lung cancer. *Clin Cancer Res*. 2007;13(3):832–838.
9. Rosell R, Perez-Roca L, Sanchez JJ, et al. Customized treatment in non-small-cell lung cancer based on *EGFR* mutations and *BRCA1* mRNA expression. *PLoS One*. 2009;4(5):e5133.
10. Meindl A, Ditsch N, Kast K, Rhiem K, Schmutzler RK. Hereditary breast and ovarian cancer: new genes, new treatments, new concepts. *Dtsch Arztebl Int*. 2011;108(19):323–330.
11. Rebbeck TR. Inherited genetic predisposition in breast cancer. A population-based perspective. *Cancer*. 1999;86(Suppl 11):2493–2501.
12. Purnomosari D, Paramita DK, Aryandono T, Pals G, van Diest PJ. A novel *BRCA2* mutation in an Indonesian family found with a new, rapid, and sensitive mutation detection method based on pooled denaturing gradient gel electrophoresis and targeted sequencing. *J Clin Pathol*. 2005;58(5):493–499.
13. Cybulski C, Górski B, Huzarski T, et al. *CHEK2* is a multiorgan cancer susceptibility gene. *Am J Hum Genet*. 2004;75(6):1131–1135.
14. Vahteristo P, Bartkova J, Eerola H, et al. A *CHEK2* genetic variant contributing to a substantial fraction of familial breast cancer. *Am J Hum Genet*. 2002;71(2):432–438.
15. Szabo CI, Kin MC. Population genetics of *BRCA1* and *BRCA2*. *Am J Hum Genet*. 1997;60(5):1013–1020.
16. Liede A, Cohen B, Black DM, et al. Evidence of a founder *BRCA1* mutation in Scotland. *Br J Cancer*. 2000;82(3):705–711.
17. Scottish/Northern Irish *BRCA1/BRCA2* Consortium. *BRCA1* and *BRCA2* mutations in Scotland and Northern Ireland. *Br J Cancer*. 2003;88(8):1256–1262.
18. Infante M, Durán M, Acedo A, et al. The highly prevalent *BRCA2* mutation c.2808_2811del (3036delACAA) is located in a mutational hotspot and has multiple origins. *Carcinogenesis*. 2013;34(11):2505–2511.

Advances in Genomics and Genetics**Dovepress****Publish your work in this journal**

Advances in Genomics and Genetics is an international, peer reviewed, open access journal that focuses on new developments in characterizing the human and animal genome and specific gene expressions in health and disease. Particular emphasis will be given to those studies that elucidate genes, biomarkers and targets in the development of new or improved therapeutic

interventions. The journal is characterized by the rapid reporting of reviews, original research, methodologies, technologies and analytics in this subject area. The manuscript management system is completely online and includes a very quick and fair peer-review system. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <http://www.dovepress.com/advances-in-genomics-and-gene-expression-journal>